Xin Lang Cai Jing·2025-10-30 02:29Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a trading volume of 279 million CNY and a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020. The company focuses on the research, production, and sales of chemical and biological new drugs [1] - The main revenue composition of the company is 99.97% from pharmaceuticals, 0.02% from pharmaceutical intermediates and raw materials, and 0.00% from asset leasing [1] Fund Holdings - A fund under Bank of China Securities holds Zai Jian Pharmaceutical as one of its top ten holdings. The fund, Zhongyin Securities Health Industry Mixed Fund (002938), reduced its holdings by 4,000 shares in the third quarter, maintaining 128,000 shares, which accounts for 9.08% of the fund's net value, ranking it as the third-largest holding [2] - The fund has a total size of 159 million CNY and has achieved a year-to-date return of 39.48%, ranking 2223 out of 8152 in its category. Over the past year, it has returned 28.41%, ranking 3260 out of 8038, and since inception, it has returned 134.28% [2] Fund Manager Information - The fund manager of Zhongyin Securities Health Industry Mixed Fund (002938) is Li Mingwei, who has been in the position for 2 years and 252 days. The fund's total asset size is 159 million CNY, with the best and worst returns during his tenure being -5.4% [3]